**Nacancell: Development of a Nanodiagnostic platform for monitoring of Cancer cell secreted proteins**

Coordinator: Arben Merkoçi, Catalan Institute of Nanoscience and Nanotechnology, Barcelona, Spain, arben.merkoci@icn2.cat

Partners: Jean-Jacques Toulmé, ARNA Laboratory, Bordeaux, France | Carmen De Torres, Hospital Sant Joan de Déu, Barcelona, Spain | Dag. Bremnes, Skannex AS, Oslo, Norway.

NACANCELL aims at developing an innovative paper-based nanodiagnostic platform to quantify parathyroid hormone-like hormone (PTHLH), a protein that exerts critical roles in cancer. The project will focus on Neuroblastoma, a childhood cancer, but will impact the field of clinical oncology and cancer research as well through its future easy application to other biomarkers.

The main objective is to generate an innovative device to monitor PTHLH production, allowing a fast, easy, cost effective monitoring, but more importantly, will provide a precise evaluation of tumor evolution and response to treatments in liquid biopsies of cancer patients. Although the project will focus on Neuroblastoma, the same principle can be applied to the vast majority of human cancers.